IQ-DAA is under clinical development by IQ Therapeutics and currently in Phase I for Anthrax. According to GlobalData, Phase I drugs for Anthrax have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IQ-DAA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IQ-DAA overview

IQ-DAA is under development for the treatment of anthrax. It is administered intravenously. It is developed using the cloning the human response technology. The technology results in antibodies which have been matured and optimized by the human immune system and are therefore most suitable for fighting infectious diseases in humans. It is a dual antibody approach using a combination of two monoclonal antibodies neutralizing the lethal toxin produced by Bacillus anthracis targeting anthrax toxin lethal factor (LF).

IQ Therapeutics overview

IQ Therapeutics is a pharmaceutical company which develops antibodies for the prevention and treatment of infectious diseases. The company is headquartered in Groningen, the Netherlands.

For a complete picture of IQ-DAA’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.